Hepion Pharmaceuticals Accounts Payables 2011-2026 | HEPA

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Hepion Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
220 K	2.35 M	2.67 M	2.45 M	3.72 M	492 K	748 K	1.56 M	4.25 M	1.48 M	244 K	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.25 M	220 K	1.83 M

Quarterly Accounts Payables Hepion Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
77.2 K	173 K	243 K	220 K	186 K	447 K	1.5 M	2.35 M	3.01 M	4.19 M	3.17 M	2.67 M	2.63 M	8.91 M	2.38 M	2.45 M	1.79 M	3.09 M	1.66 M	3.72 M	3.72 M	3.72 M	3.72 M	492 K	492 K	492 K	492 K	748 K	748 K	748 K	748 K	1.56 M	1.56 M	1.56 M	1.56 M	2.3 M	4.4 M	4.25 M	4.25 M	3.16 M	3.2 M	1.48 M	1.48 M	114 K	213 K	244 K	244 K	55.5 K	28 K	3.62 K	3.62 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.91 M	3.62 K	1.82 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
Aytu BioScience AYTU	10.6 M	$ 2.66	-	$ 16.7 M	USA
I-Mab IMAB	570 M	-	-	$ 866 M	China
Cerus Corporation CERS	28 M	$ 1.85	-	$ 353 M	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
Coherus BioSciences CHRS	9.92 M	$ 1.67	-	$ 196 M	USA
Celldex Therapeutics CLDX	1.18 M	$ 31.37	-	$ 2.08 B	USA
CollPlant Biotechnologies Ltd. CLGN	798 K	$ 0.44	-	$ 5.04 M	Israel
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
Adverum Biotechnologies ADVM	1.61 M	-	-	$ 86.2 M	USA
CNS Pharmaceuticals CNSP	1.98 M	$ 2.32	-	$ 1.03 M	USA
Catalyst Pharmaceuticals CPRX	11.2 M	$ 24.98	-	$ 3.05 B	USA
Corbus Pharmaceuticals Holdings CRBP	2.22 M	$ 10.14	-	$ 135 M	USA
Cardiff Oncology CRDF	8.09 M	$ 1.58	-	$ 106 M	USA
Curis CRIS	5.61 M	$ 0.53	-	$ 6.98 M	USA
Crinetics Pharmaceuticals CRNX	22.6 M	$ 37.7	-	$ 3.55 B	USA
CRISPR Therapeutics AG CRSP	11.1 M	$ 49.15	-	$ 4.42 B	Schweiz
AgeX Therapeutics AGE	1.93 M	-	-10.17 %	$ 12.2 K	USA
CytomX Therapeutics CTMX	1.3 M	$ 4.4	-	$ 607 M	USA
Citius Pharmaceuticals CTXR	4.93 M	$ 0.86	-	$ 5.79 M	USA
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Cue Biopharma CUE	3.95 M	$ 0.18	-	$ 17.1 M	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
DBV Technologies S.A. DBVT	40.9 M	$ 20.36	-	$ 2.84 B	France
AIkido Pharma AIKI	611 K	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	2.91 M	-	-45.71 %	$ 1.2 M	Canada
Denali Therapeutics DNLI	11.1 M	$ 19.38	-	$ 3.19 B	USA
Dyadic International DYAI	852 K	$ 0.87	-2.8 %	$ 31.5 M	USA
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
Akari Therapeutics, Plc AKTX	8.77 M	$ 3.54	-	$ 238 B	Britain
Akouos AKUS	1.28 M	-	0.23 %	$ 488 M	USA
Equillium EQ	755 K	$ 2.01	-	$ 115 M	USA
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA
Allena Pharmaceuticals ALNA	1.03 M	-	3.16 %	$ 1.9 M	USA
Alnylam Pharmaceuticals ALNY	116 M	$ 330.34	-	$ 43.3 B	USA
Alpine Immune Sciences ALPN	4.29 M	-	-	$ 2.17 B	USA
Fate Therapeutics FATE	2.66 M	$ 1.19	-	$ 141 M	USA
Aileron Therapeutics ALRN	3.98 M	-	10.36 %	$ 9.8 M	USA